Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, Hypercon™, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally. Formulating the Future of Biologics™. www.Elektrofi.com
Looking for a particular Elektrofi employee's phone or email?
The Elektrofi annual revenue was $608000 in 2026.
Chase Coffman is the Co-Founder of Elektrofi.
31 people are employed at Elektrofi.
Elektrofi is based in Boston, Massachusetts.
The NAICS codes for Elektrofi are [54, 5417, 541, 541714, 54171].
The SIC codes for Elektrofi are [873, 87].